Qiagen (NYSE:QGEN) Issues FY 2025 Earnings Guidance

Qiagen (NYSE:QGEN) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share guidance of 2.350- for the period, compared to the consensus earnings per share estimate of 2.290. The company issued revenue guidance of -. Qiagen also updated its Q1 2025 guidance to 0.550- EPS.

Wall Street Analyst Weigh In

A number of research firms recently commented on QGEN. Jefferies Financial Group reaffirmed a “buy” rating and set a $52.50 price objective (up previously from $40.83) on shares of Qiagen in a research note on Tuesday, December 10th. Morgan Stanley restated an “equal weight” rating and issued a $46.67 price objective (down from $48.61) on shares of Qiagen in a report on Monday, January 6th. Baird R W cut shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. UBS Group decreased their price target on Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Finally, Redburn Atlantic downgraded Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday. Eight investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $47.71.

Qiagen Stock Performance

Shares of QGEN opened at $38.24 on Monday. The firm has a fifty day moving average of $40.27 and a 200-day moving average of $41.94. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. The company has a market cap of $8.50 billion, a price-to-earnings ratio of 106.48, a price-to-earnings-growth ratio of 2.39 and a beta of 0.62. Qiagen has a 1 year low of $37.63 and a 1 year high of $49.30.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. As a group, equities analysts anticipate that Qiagen will post 2.26 earnings per share for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.